NCT05566041View on ClinicalTrials.gov

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

292

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Carcinoma, Small Cell Lung
Interventions
DRUG

RRx-001 + eLOOP Device

"RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device~Drug: Cisplatin/carboplatin plus etoposide Standard of care platinum doublet chemotherapy"

DRUG

Cisplatin/carboplatin plus etoposide

Standard of care platinum doublet chemotherapy

Trial Locations (2)

33612

H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa

66205

The University of Kansas Cancer Center, Westwood

Sponsors

Lead Sponsor

EpicentRx, Inc.
All Listed Sponsors
collaborator

Sciclone Pharmaceuticals (China) Co., Ltd.

UNKNOWN

lead

EpicentRx, Inc.

INDUSTRY